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Abstract
Background: Intra-aortic balloon counterpulsation (IABC) has an established role in the treatment of
patients presenting with critical cardiac illnesses, including cardiogenic shock, refractory ischemia and for
prophylaxis and treatment of complications of percutaneous coronary interventions (PCI). Patients
requiring IABC represent a high-risk subset with an expected high mortality. There are virtually no data
on usage patterns as well as outcomes of patients in the Indo-Pakistan subcontinent who require IABC.
This is the first report on a sizeable experience with IABC from Pakistan.
Methods: Hospital charts of 95 patients (mean age 58.8 (± 10.4) years; 78.9% male) undergoing IABC
between 2000–2002 were reviewed. Logistic regression was used to determine univariate and multivariate
predictors of in-hospital mortality.
Results: The most frequent indications for IABC were cardiogenic shock (48.4%) and refractory ischemia
(24.2%). Revascularization (surgical or PCI) was performed in 74 patients (77.9%). The overall in-hospital
mortality rate was 34.7%. Univariate predictors of in-hospital mortality included (odds ratio [95% CI]) age
(OR 1.06 [1.01–1.11] for every year increase in age); diabetes (OR 3.68 [1.51–8.92]) and cardiogenic shock
at presentation (OR 4.85 [1.92–12.2]). Furthermore, prior CABG (OR 0.12 [0.04–0.34]), and in-hospital
revascularization (OR 0.05 [0.01–0.189]) was protective against mortality. In the multivariate analysis,
independent predictors of in-hospital mortality were age (OR 1.13 [1.05–1.22] for every year increase in
age); diabetes (OR 6.35 [1.61–24.97]) and cardiogenic shock at presentation (OR 10.0 [2.33–42.95]).
Again, revascularization during hospitalization (OR 0.02 [0.003–0.12]) conferred a protective effect. The
overall complication rate was low (8.5%).
Conclusions: Patients requiring IABC represent a high-risk group with substantial in-hospital mortality.
Despite this high mortality, over two-thirds of patients do leave the hospital alive, suggesting that IABC is
a feasible therapeutic device, even in a developing country.
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Background
Intra-aortic balloon counterpulsation (IABC) has an
established role in the treatment of patients presenting
with cardiogenic shock [1-3], refractory heart failure [4,5],
ischemia [6] and arrhythmias [7] as well as for prophy-
laxis [8,9] and treatment of complications of percutane-
ous coronary intervention (PCI). Patients requiring IABC
represent a high-risk subset with an expected high mortal-
ity [10]. In an international registry of over 16,000 cases
selected from primarily developed nations [11], the over-
all adjusted in-hospital mortality was 21.2%. However,
there were geographic differences with lower mortality
rates in U.S. patients compared to their non-US counter-
parts (20.1% vs. 28.7%; p < 0.001) [12]. Major predictors
of mortality in these patients include age, gender, and
presentation with cardiogenic shock. There is paucity of
data on the usage patterns as well as outcomes of patients
undergoing IABC in the Indo-Pakistan region. This is
partly due to the limited availability and capacity to
implant the device as only a few centers in Pakistan have
the required logistical as well as technical expertise. Our
institution has previously reported on our initial experi-
ence of 15 patients undergoing IABC prior to coronary
artery bypass graft (CABG) surgery [13]. We now report on
an extended experience with intra-aortic balloon counter-
pulsation and describe the patterns of usage as well as the
independent predictors of in-hospital mortality in
patients undergoing IABC.
Methods
Patient population
We reviewed the charts of 95 patients undergoing IABC at
the Aga Khan University Hospital (AKUH), Karachi, Paki-
stan between January 2000 and December 2002. Patients
requiring IABC in the operating room immediately fol-
lowing CABG to assist weaning off cardiopulmonary
bypass were excluded from this study. However, those
patients who underwent IABP implantation prior to sur-
gery were included. The AKUH is a tertiary care hospital
located in the metropolitan city of Karachi that receives a
mixture of affluent as well as low and middle income
patients and serves the entire city as a referral center for
patients requiring high-intensity tertiary care. Variables
collected included age, gender, indication for IABC (shock
or non-shock), history of diabetes, hypertension, smok-
ing, prior PCI or CABG, left ventricular function, refrac-
tory ischemia and treatment (revascularization vs. no
revascularization). Cardiogenic shock was defined as a
systolic blood pressure (SBP) of < 90 mm Hg for at least
30 minutes (or requirement of inotropes to maintain a
SBP > 90 mm Hg) associated with hypoperfusion
(decreased urine output or cool extremities) and a heart
rate of ≥ 60 beats per minute. Left ventricular (LV) ejection
fraction (EF) was assessed by visual estimation. LV func-
tion was recorded as normal for an EF of ≥ 55%, mildly
impaired for an EF 40–54%, moderately impaired for an
EF 26–39% and severely impaired if the EF was ≤ 25%.
Heart failure was diagnosed using clinical signs as defined
by the Framingham criteria [14]. Refractory heart failure
was defined as heart failure failing to respond to therapy
including inotropic support. Refractory ischemia was
defined as on-going ischemic chest pain and/or dynamic
ECG changes (ST depression or ST elevation ≥ 1 mm in
two or more contiguous leads) despite adequate medical
therapy including antiplatelet drugs, beta-blockers and
heparin. The outcome of interest was in-hospital
mortality.
Statistical methods
All variables were entered into Statistical Package for
Social Sciences (SPSS) version 10. Means and standard
deviations were calculated for continuous variables and
frequencies for categorical variables. Variables were ana-
lyzed by simple logistic regression to calculate the unad-
justed odds ratios for factors associated with in-hospital
mortality. Those variables with a p value of ≤ 0.25 on uni-
variate analysis were entered into the multivariable model
and adjusted odds ratios for factors associated with in-
hospital mortality were calculated. Finally, the model fit
was assessed using the Hosmer-Lameshow test. A p value
of < 0.05 was considered significant.
Results
Table 1 summarizes the patient characteristics. The mean
age of the study group was 58.8 (± 10.4) years. The major-
ity of subjects were male (78.9%) and a high proportion
had hypertension (55.8%), diabetes (43.2%), a smoking
history (37.9%), previous PCI (30.5%) or CABG (48.4%).
About half (48.4%) of the patients presented with cardio-
genic shock and a similar number (52.6%) had moderate
or severe depression of left ventricular function at presen-
tation. All except two patients underwent coronary angi-
ography and over two-thirds had three-vessel coronary
artery disease. A revascularization procedure (either surgi-
cal or PCI) was performed in 74 patients (77.9%). In the
remaining 21 patients, the main reasons for not perform-
ing revascularization were as follows: diffuse disease not
amenable to PCI or CABG (5 patients), CABG felt to be
too high-risk on account of comorbid conditions (6
patients), death in the catheterization laboratory prior to
revascularization (6 patients), failed PCI (1 patient) and
no need for revascularization (3 patients). The overall in-
hospital mortality rate in this study group was 34.7% with
six patients (6.3%) dying in the laboratory while the
remaining 27 (28.4%) died during the hospital stay. Sixty-
five patients (65.3%) left the hospital alive.
Table 2 shows the indications for the implantation of an
intra-aortic balloon pump (IABP). Almost half were
inserted for cardiogenic shock. In the univariate analysis
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(Table 3), variables associated with in-hospital mortality
included (odds ratio [95% CI]) age (OR 1.06 [1.01–1.11]
for every year increase in age; diabetes (OR 3.68 [1.51–
8.92]) and cardiogenic shock at presentation (OR 4.85
[1.92–12.2]); left ventricular dysfunction, hypertension
and 3-vessel (versus no 3-vessel) coronary artery disease
were not significantly associated with in-hospital mortal-
ity in these patients. A significant protective effect of a
prior history of CABG surgery (OR 0.12 [0.04–0.34]) and
in-hospital revascularization, either surgical or percutane-
ous, (OR 0.05 [0.01–0.189]) was noted in this study.
In the multivariate analysis (Table 4), the significant inde-
pendent predictors of in-hospital mortality were age (OR
1.13 [1.05–1.22] for every year increase in age); diabetes
(OR 6.35 [1.61–24.97]) and cardiogenic shock at presen-
tation (OR 10.0 [2.33–42.95]). Revascularization during
hospitalization remained a significant protective factor
against mortality (OR 0.02 [0.003–0.12]) The Hosmer-
Lemeshow test indicated a good fit for the model (χ2 6.09;
p = 0.637). In the adjusted analysis, a prior history of
CABG did not remain a significant predictor of survival
primarily because forty-five out of 46 patients underwent
revascularization.
When age as a risk factor was further analyzed by plotting
an ROC curve, an age cut-off of 66.5 years had a high spe-
cificity for the outcome of in-hospital mortality (specifi-
city 83.9%; area under ROC-curve 0.66; p = 0.01). Thus
older patients requiring IABC suffer worse outcomes than
younger subjects.
The overall complication rate related to the device
implantation was low. Eight patients (8.5%) developed
limb ischemia necessitating removal of the IABP; how-
ever, only one of these eight required surgery. There were
no significant bleeding complications although one
Table 1: Patient Characteristics.
Characteristic N (%)*
Age (mean/SD) 58.8 (10.4)
Males 75 (78.9)
Female 20 (21.1)
Diabetes 41 (43.2)
Hypertension 53 (55.8)
Smoking 36 (37.9)
Previous PCI 29 (30.5)
Previous CABG 46 (48.4)
Coronary Anatomy
Single vessel disease 6 (6.3)
2-vessel disease 15 (15.8)
3-vessel disease 72 (75.8)
LV function – normal or mildly impaired 45 (47.4)
LV function – moderate or severely impaired 50 (52.6)
Cardiogenic shock 46 (48.4)
Underwent revascularization 74 (77.9)
Percutaneous 26 (27.4)
Surgical 48 (50.5)
* mean/Standard Deviation for age; (%) for others
LV = left ventricular; PCI = percutaneous coronary intervention; 
CABG = coronary artery bypass grafting
Table 2: Indications for Intra-aortic balloon counterpulsation
Indication N (%)
Cardiogenic shock 22 (23.2)
Cardiogenic shock with mechanical complication 24 (25.3)
Left Main disease, no chest pain 9 (9.5)
Left Main disease, chest pain in laboratory 6 (6.3)
Refractory heart failure 8 (8.4)
Refractory Ischemia 23 (24.2)
Complication during PCI 2 (2.1)
PCI = percutaneous coronary intervention (includes abrupt closure, 
severe "no-reflow")
Table 3: Univariate Predictors of In-Hospital Mortality
Survived (%) (n = 62) Died (%) (n = 33) Unadjusted OR (95% CI) p value
Age (SD) 56.9 (10.1) 62.5 (10.3) 1.06 (1.01–1.11) * 0.016
Male Gender 51 (82.3) 24 (72.7) 0.58 (0.21–1.57) 0.281
Diabetes 20 (32.3) 21 (63.6) 3.68 (1.51–8.92) 0.004
Hypertension 32 (51.6) 21 (63.6) 1.64 (0.69–3.93) 0.263
Smoking 25 (40.3) 11 (33.3) 1.35 (0.56–3.27) 0.504
Previous PCI 20 (32.3) 9 (27.3) 0.79 (0.31–2.0) 0.616
Previous CABG 40 (64.5) 6 (18.2) 0.12 (0.04–0.34) <0.001
Cardiogenic Shock 22 (35.5) 24 (72.7) 4.85 (1.92–12.2) 0.001
3-vessel disease** 44 (72.1) 28 (87.5) 2.70 (0.83–8.89) 0.101
LV dysfunction *** 30 (48.4) 20 (60.6) 1.64 (0.70–3.87) 0.258
Revascularized 58 (95.1) 16 (48.5) 0.05 (0.01–0.19) < 0.001
SD = standard deviation. PCI = percutaneous coronary intervention. CABG = coronary artery bypass graft. LV = left ventricular
* for every 1 year increase in age
** vs. no 3-vessel disease
*** moderate/severely impaired LV function vs. normal/mildly impaired
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patient developed a hematoma following removal of the
device; however this patient did not require blood trans-
fusion or surgical repair of the arteriotomy site.
Discussion
Patients requiring IABC are at high risk for death on
account of their critical underlying conditions. Despite
this, several data have suggested that IABC can improve
morbidity and mortality in specific subsets of patients
including those presenting with cardiogenic shock. The
use of IABC in developing countries is limited on account
of lack of equipment as well as skilled personnel who can
insert and manage the device. Ours is the first report on a
sizeable experience with IABC from the Indo-Pakistan
subcontinent. Our experience is similar to that of other
centers in the West. We report a high in-hospital mortality
rate in patients undergoing IABC (almost 35%). However,
given that nearly half of the subjects had cardiogenic
shock at presentation, this mortality rate is reasonably
acceptable. Advanced age (over 66.5 years), diabetes and
cardiogenic shock at presentation were strong independ-
ent predictors of in-hospital mortality, while revasculari-
zation (either surgical or PCI) was associated with high
odds of survival. The latter finding is consistent with
recently reported data from the IABP Benchmark Registry
[15]. Of particular interest is the finding that patients with
a prior history of CABG were more likely to survive, a
finding driven by the fact that the majority underwent
revascularization. This suggests that repeat revasculariza-
tion of patients with a prior history of bypass surgery (a
clearly high-risk subset) is not only feasible but also effec-
tive in a developing country setting. Our complication
rates were acceptably low, supporting the feasibility of
using IABC in our setting.
Several limitations of this study should be acknowledged.
First, the sample size is fairly small and this is reflected in
the relatively wide confidence intervals for the odds ratios.
Due to a small sample size, it is difficult to make a com-
parison of correlates of mortality between subgroups, for
example those presenting with cardiogenic shock versus
those who did not and those undergoing surgical versus
percutaneous revascularization. However, as expected,
patients presenting with shock had a significantly higher
mortality (72.7% vs. 27.3%; p = 0.001). Second, the
patient group selected may not be representative of other
centers in Pakistan given that our institution is a unique
tertiary care hospital in the country. Third, our cohort did
not contain patients undergoing prophylactic IABC prior
to high-risk PCI for indications other than cardiogenic
shock. This probably represents practice patterns at our
institution whereby, largely due to cost constrains, very
high-risk patients (for example those with multivessel dis-
ease and/or severe impairment of LV function) are prefer-
entially send for surgery. The cumulative cost of IABC with
multivessel stenting far exceeds that of a bypass operation.
Only two patients required emergent IABC during PCI in
the study period. This may reflect a selection of lower risk
patients for PCI at our institution. Fourth, while the sur-
vival rate following IABC is nearly 65%, no analysis has
been made of the cost effectiveness of this therapy.
Conclusions
In conclusion, cardiogenic shock and refractory ischemia
are common indications for IABC in a Pakistani setting.
Patients requiring an IABP represent a high-risk group
with substantial in-hospital mortality. This is consistent
with the nature of the presenting illnesses in these patients
and is similar to western data. Despite this high mortality,
over two-thirds of patients do leave the hospital alive, sug-
gesting that IABC is a feasible therapeutic device, even in
a developing country. Age (particularly over 66.5 years),
diabetes and cardiogenic shock at presentation are signif-
icant predictors of mortality in this group of patients.
Revascularization is a significant predictor of survival and
complication rates are acceptably low. Larger studies are
needed to evaluate which subsets of patients benefit the
most from this device and further cost effectiveness anal-
yses are warranted.
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Table 4: Multivariate Predictors of In-hospital Mortality*
Survived (%) (n = 62) Died (%) (n = 33) Adjusted OR (95% CI) p value
Age (SD) 56.9 (10.1) 62.5 (10.3) 1.13 (1.05–1.22) * 0.001
Diabetes 20 (32.3) 21 (63.6) 6.35 (1.61–24.97) 0.008
Cardiogenic Shock 22 (35.5) 24 (72.7) 10.0 (2.33–42.95) 0.002
Revascularized 58 (95.1) 16 (48.5) 0.02 (0.003–0.12) < 0.001
* adjusted for gender, previous CABG, hypertension and LV dysfunction (none/mild vs. moderate/severe). Hosmer-Lemeshow χ2 6.09; p = 0.637
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